Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD20
  • Antineoplastic Agents
  • Drug Resistance, Neoplasm
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Vidarabine

abstract

  • Ofatumumab is an active, well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patients with very poor-prognosis CLL.

publication date

  • April 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4979101

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.25.3187

PubMed ID

  • 20194866

Additional Document Info

start page

  • 1749

end page

  • 55

volume

  • 28

number

  • 10